NASDAQ:MTVA MetaVia Q3 2025 Earnings Report $1.63 0.00 (0.00%) Closing price 09/24/2026 04:00 PM EasternExtended Trading$1.68 +0.05 (+3.01%) As of 09/24/2026 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast MetaVia EPS ResultsActual EPS-$1.54Consensus EPS -$2.86Beat/MissBeat by +$1.32One Year Ago EPSN/AMetaVia Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMetaVia Announcement DetailsQuarterQ3 2025Date11/6/2025TimeBefore Market OpensConference Call DateThursday, November 6, 2025Conference Call Time8:30AM ETUpcoming EarningsMetaVia's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) MetaVia Earnings HeadlinesMTVA: Preclinical Findings Support DA-1726 Waist Circumference ReductionSeptember 10, 2026 | finance.yahoo.comMetaVia Inc.: MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference ReductionSeptember 9, 2026 | finanznachrichten.deThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason. | Banyan Hill Publishing (Ad)MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference ReductionSeptember 9, 2026 | prnewswire.comMTVA: Dose Titration Complete in Phase 1 Part 3 Study of DA-1726August 12, 2026 | finance.yahoo.comMetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 6, 2026 | prnewswire.comSee More MetaVia Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like MetaVia? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MetaVia and other key companies, straight to your email. Email Address About MetaViaMetaVia (NASDAQ:MTVA), Inc. is a clinical-stage biopharmaceutical company focused on developing peptide-based medicines for obesity, metabolic disorders and related diseases. The company’s programs are designed to address conditions such as obesity-associated liver disease and other complications of metabolic dysfunction. MetaVia’s lead product candidate is pemvidutide, an investigational once-weekly dual GLP-1 and glucagon receptor agonist. The company is evaluating pemvidutide for chronic weight management and metabolic dysfunction-associated steatohepatitis, now commonly referred to as metabolic dysfunction-associated steatohepatitis or MASH. The treatment is intended to combine weight-loss effects with potential benefits for liver health and broader metabolic function. The company was formerly known as Altimmune, Inc. and changed its corporate name to MetaVia. Based in the United States, MetaVia conducts clinical development activities intended to support potential commercialization in major global healthcare markets. Vipin K. Garg has served as the company’s president and chief executive officer.View MetaVia ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Restaurant Stocks Near 52-Week Lows as Consumer Pressure BuildsPaychex Plunges, Providing the Entry Investors Have Been Waiting ForThe Case for Buying High-Yield General Mills Just StrengthenedEnergy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock? Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
